News & Events about Gilead Sciences Inc.
TipRanks Financial Blog
1 year ago
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amneal Pharmaceuticals (AMRX Research Report), Replimune Group ... Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amneal Pharmaceuticals (AMRX Research Report), Replimune Group...
Hennion & Walsh Asset Management Inc. lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD Free Report) by 7.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,569 shares of the biopharmaceutical ...
Altfest L J Co. Inc. trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD Free Report) by 7.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities Exchange Commission. The institutional investor owned 3,747 ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced Week 96 results from the pivotal MYR301 Phase 3 clinical trial evaluating the first-in-class entry inhibitor Hepcludex (bulevirtide) for the treatment of adults with chronic hepatitis delta (HDV) infection. These new data presented at the...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Trodelvy (sacituzumab govitecan) as monotherapy for the treatment of adult patients with unresectable or...